WDA Licensing and UK Pharmaceutical Export Regulations: A Complete Guide

The UK pharmaceutical supply chain is one of the most tightly regulated in the world. For procurement teams and importers sourcing medicines from British suppliers, understanding the regulatory framework that governs these suppliers is essential. The foundation of that framework is the Wholesale Dealer Authorisation (WDA), the mandatory licence that allows a company to legally distribute pharmaceutical products in the United Kingdom.

This guide covers everything procurement teams need to know about WDA licensing: what it is, how it is obtained, what it requires, how the MHRA inspects and enforces it, and most importantly, how to verify that a potential supplier holds a valid licence. Whether you are a hospital pharmacist, a health ministry buyer, or a procurement officer for a regional distributor, understanding WDA licensing is critical to ensuring you source medicines from a compliant, regulated supplier.

What Is a WDA Licence?

A Wholesale Dealer Authorisation (WDA) is the legal permission granted by the MHRA (Medicines and Healthcare Products Regulatory Agency) that allows a company to wholesale pharmaceutical products in the UK. “Wholesale” in this context means buying, storing, and selling medicines, either to retailers (pharmacies, hospitals) or directly to patients through NHS dispensing or hospital wards.

Without a WDA, a company cannot legally distribute prescription medicines, controlled drugs, or certain veterinary products in the UK. This is not a voluntary accreditation or a best-practice standard. It is a legal requirement enforced under the Human Medicines Regulations 2012 and the Medicines Act 1968.

The MHRA issues and manages all WDA licences in the UK. The regulator has the power to grant, renew, suspend, or revoke a WDA based on whether the company meets and continues to meet strict regulatory standards. These standards cover:

• Physical premises: Storage facilities, cleanrooms, temperature-controlled areas, and secure storage for controlled drugs
• Personnel: A Responsible Person with specific qualifications, trained staff, and documented competency
• Quality systems: Standard operating procedures (SOPs), documentation protocols, and record-keeping
• Good Distribution Practice (GDP): Compliance with the quality standards that govern how pharmaceuticals are handled
• Traceability: The ability to track products through the supply chain and identify and remove defective or counterfeit medicines

WDA(H) vs WDA(IMP): Two Types of Authorisation

The MHRA operates a tiered system of WDA licensing. It is important to understand the difference between the two main categories, especially if you are sourcing directly from a UK supplier.

The key distinction is importation. A company holding WDA(H) only can receive medicines that have already been imported into the UK and distribute them. But they cannot themselves import medicines from a non-UK manufacturer or supplier.

A company holding WDA(H) plus WDA(IMP) can both import medicines into the UK and distribute them. For a procurement team importing into the UK, the supplier should ideally hold WDA(IMP) if they are importing the product directly from a manufacturer, or WDA(H) if they are sourcing the product from another UK-based licensed distributor.

Who Needs a WDA Licence?

Any company in the UK that buys and sells (wholesales) pharmaceutical products must hold a WDA. This includes:

• Large pharmaceutical wholesalers: Companies like Cardinal Health, Phoenix, and Alliance that distribute to pharmacies and hospitals across the UK
• Specialist wholesalers: Companies that focus on specific product categories (oncology, controlled drugs, unlicensed medicines, named patient medicines, etc.)
• Pharmaceutical importers: Companies that source medicines from overseas manufacturers or distributors and import them into the UK
• Hospital pharmacy manufacturing units: Hospital departments that prepare medicines for patients
• Authorized wholesalers in special circumstances: Hospitals or GPs granted limited WDA authority to supply certain medicines

The MHRA publishes a publicly searchable register of all WDA-licensed companies. This register is the authoritative list of legal pharmaceutical wholesalers in the UK.

The MHRA WDA Application Process

Obtaining a WDA licence is a rigorous process that typically takes 3 to 6 months from initial application to licence grant. The process involves:

Step 1: Pre-Application Planning

Before submitting a formal application, the company must ensure it meets all the prerequisites: suitable premises secured (or under development), key personnel identified, quality systems drafted, and GDP procedures documented. Many applicants engage MHRA consultants during this phase to ensure their documentation and systems are aligned with regulatory expectations.

Step 2: Formal Application Submission

The applicant submits a formal application to the MHRA including:

• Details of the company structure and ownership
• Detailed description of the premises (floor plans, storage areas, cleanroom specifications if applicable)
• Information about the Responsible Person (qualifications, experience, contact details)
• Organisational chart and details of key personnel
• Standard Operating Procedures (SOPs) for all critical processes
• Quality systems documentation
• GDP compliance evidence
• Fee payment (currently £2,000 for a new WDA application)

Step 3: Initial Assessment

MHRA case officers review the application for completeness. If documents are missing or unclear, the case officer will request additional information (Requests for Further Information, or RFIs). The applicant must respond to RFIs within a specified timeframe, typically 10 to 20 days.

Step 4: Pre-Inspection Recommendation

Once the MHRA is satisfied with the submitted documentation, the case officer recommends the application for inspection. At this point, an inspection date is scheduled with the applicant.

Step 5: MHRA Inspection (Initial or Pre-Licence Inspection)

An MHRA team typically comprising 2 to 4 inspectors conducts an unannounced or pre-scheduled inspection of the applicant's premises. During this inspection, they will:

• Verify the physical premises match the application
• Confirm storage conditions, temperature monitoring, and security
• Assess staff training and competency
• Review documentation systems and GDP compliance
• Observe operational processes
• Conduct interviews with staff, particularly the Responsible Person

Step 6: Inspection Report and Follow-Up

Following the inspection, the MHRA issues a detailed report outlining any observations, minor deficiencies, or major deficiencies. The applicant must address all deficiencies in writing and provide evidence of corrective action. Major deficiencies must be resolved and reported back within 30 days, while minor observations may have a longer timeline.

Step 7: Licence Decision

Once all deficiencies are resolved to the MHRA's satisfaction, the agency issues the WDA licence. The licence is granted for a period of 3 years (from 2024, following regulatory changes; previously licences were issued for 5 years). The licence document specifies:

• The company name and address
• The Responsible Person's name and qualifications
• The scope of the licence (WDA(H) only, or WDA(H) + WDA(IMP))
• Any specific conditions or limitations
• The licence expiry date and renewal requirements

GDP Requirements Under WDA Licensing

Good Distribution Practice (GDP) is not a separate licence. Rather, it is the quality and safety standard that underpins the WDA licensing system. A company cannot obtain or maintain a WDA without demonstrating continuous GDP compliance.

Key GDP Requirements

Temperature Monitoring and Control: All storage areas where temperature-sensitive medicines are held must have continuous temperature monitoring with calibrated sensors. Cold storage units must be temperature-mapped annually, and any temperature excursion must be detected, recorded, and investigated. Out-of-hours alarm monitoring is required.

Documentation and Traceability: Every receipt and dispatch of medicines must be documented, with clear records of who supplied the medicine, what it was, how many units, and who it was sold to. This enables traceability, the ability to identify and locate specific batches of medicine throughout the supply chain.

Quality Assurance: The company must have procedures for identifying and handling substandard, counterfeit, or recalled medicines. This includes quarantine protocols, root cause investigation procedures, and documented corrective actions.

Staff Training: All staff involved in the receipt, storage, or dispatch of medicines must receive initial training and ongoing refresher training on GDP and the company's procedures. Training records must be maintained.

Premises and Storage: Storage facilities must be kept clean, secure, and at the correct temperature and humidity. Medicines must be stored in a way that prevents contamination and ensures first-in, first-out (FIFO) rotation to minimise the risk of expired stock being dispensed.

Supplier Management: The wholesaler must verify that their suppliers are legitimate and properly licensed. This includes confirmation that pharmaceutical manufacturers and other suppliers hold the appropriate manufacturing or wholesale licences.

Physical Site Requirements for WDA Licensing

The MHRA has detailed requirements for the physical premises of a WDA-licensed wholesaler. These requirements ensure that medicines are stored safely and securely throughout the supply chain.

Storage Conditions

Premises must include appropriate storage facilities for the types of medicines being held. This includes:

• General storage areas (controlled room temperature, typically 15°C to 25°C)
• Cold storage facilities (typically 2°C to 8°C) for vaccines, biologics, insulin, and other refrigerated medicines
• Secure storage for controlled drugs (locked cabinets or dedicated controlled-drug rooms with restricted access)
• Potentially frozen or ultra-cold storage for specialised products (−20°C or below)

Cleanroom Standards

If the wholesaler repackages or performs any manipulations on medicines (beyond simple reboxing), they may be required to operate a cleanroom meeting European cleanroom classification standards (typically Grade C or D). This is an area with controlled air quality, filtered air supply, and documented environmental monitoring.

Security and Access Control

The premises must have restricted access, with controlled entry via key cards or biometric systems where appropriate. CCTV may be required for high-value product areas. Controlled drugs storage areas require additional security measures, including alarm systems and restricted key access.

Utilities and Backup Systems

For cold storage facilities, backup refrigeration capacity is often required. Power supply to critical areas should have backup generators or uninterruptible power supply (UPS) systems. Water supply and drainage must meet specified standards.

The Responsible Person: Qualifications and Duties

Every WDA-licensed wholesaler must have a named Responsible Person (RP), a senior individual with specific qualifications and legal responsibility for the company's compliance with pharmaceutical regulations.

Responsible Person Qualifications

The MHRA requires the RP to have:

• A university degree in pharmacy, chemistry, or a related pharmaceutical science discipline, OR equivalent professional qualifications and experience
• Knowledge of pharmaceutical regulations and GDP requirements
• Experience in pharmaceutical distribution or manufacturing (typically at least 2 years in a supervisory role)
• Competency in the specific business the company operates (e.g., if the company handles controlled drugs, the RP must be competent in controlled drug regulations)

The RP does not need to be a pharmacist, but they must have relevant pharmaceutical training and experience recognised by the MHRA.

Responsible Person Duties

The RP is personally accountable for:

• Ensuring all operations comply with GDP and pharmaceutical regulations
• Reviewing and approving all standard operating procedures
• Ensuring staff are appropriately trained
• Overseeing quality assurance and product recall procedures
• Investigating and reporting any significant compliance issues to the MHRA
• Maintaining records and responding to regulatory enquiries

If a Responsible Person leaves the company, the wholesaler must notify the MHRA within 14 days and appoint a successor. During the transition, a temporary arrangement may be permitted, but the MHRA must approve any permanent replacement.

Ongoing Compliance and MHRA Inspections

Obtaining a WDA is not the end of the regulatory journey, it is the beginning. MHRA licence holders are subject to ongoing inspections and must maintain continuous compliance with GDP and MHRA regulations.

Inspection Frequency

The MHRA conducts risk-based inspections of WDA-licensed wholesalers. The frequency depends on factors including:

• The size and scope of the business (larger wholesalers are typically inspected more frequently)
• The complexity of the products handled (companies handling more high-risk products face more frequent inspections)
• Compliance history (companies with previous deficiencies or incidents are inspected more frequently)
• Any specific regulatory concerns (a shortage or contamination incident in a product category might trigger inspections of all companies handling that category)

Typically, a standard wholesaler is inspected every 2 to 4 years. Specialist wholesalers (e.g., those handling controlled drugs or unlicensed medicines) may be inspected annually or biannually. Large national wholesalers may face inspections every 1 to 2 years.

What Happens During an Inspection

MHRA inspections are unannounced (except in exceptional circumstances). An inspection team typically comprising 2 to 4 inspectors will arrive at the premises with an inspection warrant. They will:

• Review all relevant documentation (SOPs, staff training records, supplier audits, quality records)
• Conduct a physical inspection of the premises
• Interview staff at various levels, from warehouse operatives to management
• Test the company's ability to trace specific medicines through the supply chain
• Review handling procedures for errors or deviations
• Assess the Responsible Person's oversight of the operation
• Check on any previous deficiencies to confirm corrective actions were effective

Inspections typically last 1 to 3 days, depending on the size of the company and the scope of the inspection.

Inspection Outcomes

Following an inspection, the MHRA issues a formal report to the company. The report may include:

• No deficiencies: The company is fully compliant and meets all requirements
• Minor observations: Non-compliance with relatively minor or low-risk implications. These must be corrected, typically within 90 days
• Major deficiencies: Significant deviations from GDP or MHRA requirements that could affect the quality or safety of medicines. These must be corrected within 30 days and reported back to the MHRA
• Critical deficiencies: Serious breaches that pose an immediate risk. The MHRA may suspend or revoke the licence, issue a warning letter, or impose immediate operational restrictions

The company must respond in writing to all deficiencies, explaining the corrective actions taken and providing supporting evidence. The MHRA may conduct a follow-up inspection to verify that corrective actions have been effective.

Common Deficiencies Found During WDA Inspections

MHRA inspection reports are published (in redacted form) on the MHRA website, allowing industry observers to understand the most common compliance issues. Based on published inspection reports, the following deficiencies are frequently identified:

How to Verify a WDA-Licensed Supplier

For procurement teams and importers, verifying that a potential supplier is WDA-licensed is straightforward and essential. Here is how to do it:

Step 1: Check the MHRA Public Register

The MHRA maintains a publicly accessible register of all WDA-licensed pharmaceutical wholesalers. Visit the MHRA website (www.mhra.gov.uk) and navigate to the Licensing section. You can search by company name, address, or licence number. The register shows:

• Company name and address
• Type of licence (WDA(H) and/or WDA(IMP))
• Licence number
• Name of the Responsible Person
• Licence grant date and expiry date

Verify that the company name, address, and licence scope match what the supplier claims. If the company is not on the register, or if the licence has expired, the company is operating illegally.

Step 2: Review Published Inspection Reports

The MHRA publishes inspection reports on its website, typically 12 months after the inspection. These reports (with commercially sensitive information redacted) provide detailed insights into the company's compliance history. Review the most recent available report for:

• Date of the last inspection
• Any deficiencies identified
• The severity of deficiencies (minor, major, or critical)
• Whether previous deficiencies have been resolved

A company with regular inspections and no major deficiencies is generally a reliable choice. A company with frequent major deficiencies, or deficiencies related to temperature control or product quality, warrants further investigation.

Step 3: Contact the Company for Proof of Licence

For due diligence on significant orders, request the supplier provide a copy of their current WDA licence certificate. This is a standard request and reputable suppliers will provide it promptly. Cross-reference the licence details with the MHRA register.

Step 4: Request GDP Compliance Evidence

Before placing an initial order, ask the supplier to provide:

• Documentation of their temperature monitoring procedures (for cold chain products)
• Details of their validated cold chain packaging systems
• Information about their staff training program
• An overview of their quality assurance procedures
• Evidence of supplier audits (particularly if you are concerned about the origin of medicines)

Professional suppliers will have this documentation readily available. If a company is reluctant or unable to provide basic GDP documentation, it is a red flag.

Step 5: Assess Their Knowledge of Your Market

Ask the supplier about their experience exporting to your country. Do they know the regulatory requirements, customs procedures, and import paperwork needed? A UK supplier with established experience in your market is likely to have proven processes and fewer delivery complications.

Why WDA Licensing Matters for International Buyers

For procurement teams and hospitals importing medicines from the UK, WDA licensing is fundamentally important. Here is why:

Quality Assurance: A WDA-licensed supplier is subject to regular MHRA inspections and must maintain documented quality systems. This reduces the risk of receiving substandard, counterfeit, or incorrectly stored medicines.

Legal Protection: Purchasing from a licensed wholesaler protects both you and your institution legally. If something goes wrong (contamination, incorrect product, loss of cold chain), a licensed wholesaler has documented procedures and traceability systems that help investigate the incident. An unlicensed supplier provides no such protection.

Regulatory Compliance: Many countries, when assessing pharmaceutical imports, verify that the supplying wholesaler is licensed in their country of origin. A UK WDA licence demonstrates to your national regulator that the supplier is operating under UK pharmaceutical law.

Supply Chain Integrity: WDA licensing includes requirements for supplier audits and traceability. A licensed wholesaler will verify that their suppliers (whether manufacturers or other wholesalers) are themselves legitimate. This helps prevent counterfeit medicines from entering the supply chain.

Access to Specialist Products: Some pharmaceutical products (named patient medicines, unlicensed medicines, clinical trial medicines) can only be legally distributed by WDA-licensed wholesalers with specific authorisation for these categories. If you need access to these products, your supplier must hold the appropriate licence scope.

Frequently Asked Questions

What is a WDA licence and why do pharmaceutical wholesalers need one?

A WDA (Wholesale Dealer Authorisation) is the mandatory regulatory permission issued by the MHRA that allows a company to legally distribute pharmaceutical products in the UK. Without a WDA, a company cannot wholesale prescription medicines, controlled drugs, or certain veterinary products. The licence is granted based on strict criteria including premises standards, qualified personnel, quality systems, and Good Distribution Practice (GDP) compliance. For importers and procurement teams, confirming that a supplier holds a valid WDA is the essential first verification step before placing an order.

What is the difference between WDA(H) and WDA(IMP) licences?

WDA(H) is the standard Wholesale Dealer Authorisation for holding and distributing pharmaceuticals within the UK supply chain. WDA(IMP) is an additional authorisation that permits a company to import pharmaceutical products directly into the UK from non-UK suppliers or manufacturers. A company can hold WDA(H) alone (meaning they cannot import directly) or WDA(H) plus WDA(IMP) (meaning they can both import and distribute). For procurement teams importing into the UK, verify that the supplier holds at least WDA(H); if they claim to import directly from manufacturers, they should have WDA(IMP) as well.

What is GDP and how does it relate to WDA licensing?

GDP stands for Good Distribution Practice, the quality and safety standard that governs how pharmaceutical products are stored, transported, handled, and documented throughout the supply chain. GDP is not optional advice, it is a legal requirement enforced through the WDA licensing system. The MHRA will only grant or renew a WDA licence if the company demonstrates full GDP compliance through documented procedures, staff training, quality systems, and physical premises standards. During MHRA inspections, inspectors assess GDP compliance, and any significant deviations result in deficiency findings that must be corrected.

How often does the MHRA inspect WDA-licensed wholesalers?

The MHRA conducts risk-based inspections of WDA-licensed wholesalers every 2 to 4 years on average, though frequency varies based on company size, product complexity, and compliance history. Specialist wholesalers (e.g., handling controlled drugs) may be inspected annually. Inspections are unannounced and can occur at any time. During an inspection, MHRA officers review documentation, observe operations, interview staff, and assess compliance with GDP regulations. The outcome is a formal report published (in redacted form) on the MHRA website.

How can I verify that a pharmaceutical supplier holds a valid WDA licence?

The MHRA publishes a public register of all WDA-licensed wholesalers at www.mhra.gov.uk. Search the register by company name to verify current licence status, check the scope of the licence (WDA(H) and/or WDA(IMP)), review the Responsible Person, and access published inspection reports. For significant orders, request the supplier provide a copy of their licence certificate and compare it against the MHRA register. Additionally, review their published inspection reports for any deficiencies or compliance issues. A company not appearing on the register is operating illegally and should be avoided.